文献速递慢性静脉疾病

下肢淋巴水肿间歇气压治疗随机对照试验的系统综述

A systematic review of contemporary randomized controlled trials for treatment of lower extremity lymphedema by intermittent pneumatic compression devices.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-04-15

该系统综述检索2010年至2025年的随机对照试验,最终纳入7项下肢淋巴水肿研究,平均样本量54例,平均年龄55岁,女性占67%。所有7项研究均显示间歇气压治疗(IPC)显著减少肢体体积,5项研究组间比较也显示水肿减轻差异;GRADE评价为中等确定性证据,方法学质量中等。

要点

  • IPC可显著减少下肢淋巴水肿肢体体积,7项RCT组内比较均显著。
  • 5项RCT组间比较显示IPC在减轻水肿方面优于对照。
  • 证据确定性中等,偏倚风险中等,异质性妨碍荟萃分析。

核心结论

  • IPC治疗下肢淋巴水肿可显著减少肢体体积,组内比较全部显著,组间比较5/7项显著。
  • GRADE评价显示中等确定性证据支持IPC减少下肢水肿、体积或周径。
  • 方法学质量总体为中等,偏倚风险中等。

研究设计与样本

  • 系统综述基于PICO问题,检索CINAHL、Embase和MEDLINE,时间2010年1月1日至2025年1月31日。
  • 采用PRISMA报告方法,共初筛145篇 eligible RCT,最终纳入7项下肢淋巴水肿RCT。
  • 纳入标准:成人≥18岁,单侧或双侧慢性下肢淋巴水肿≥6个月且处于维持期,踝肱指数≥0.8,无活动性感染或急性静脉血栓。
  • 7项RCT平均患者总数54例,平均年龄55岁,女性占67%。
  • 5项RCT为两组,2项为三组;实验组5项使用高级气压装置,其中3项联合复杂消肿治疗。

主要发现

  • 所有7项RCT均报告肢体体积减少,基线至治疗结束组内比较有统计学显著差异。
  • 5项RCT组间比较显示水肿减轻存在差异。
  • 5项RCT报告患者报告结局,其中3项组内比较显示生活质量显著改善。
  • 慢性静脉功能不全是7项RCT中最常见病因;多数为继发性淋巴水肿,3项包含部分原发性淋巴水肿。
  • 异质性和实验/对照组构成妨碍荟萃分析。

关键数值与推荐

  • 纳入RCT需满足:年龄≥18岁,慢性下肢淋巴水肿≥6个月且处于维持期,踝肱指数≥0.8,无活动性感染或急性静脉血栓。
  • 主要结局为肢体体积减少,所有7项RCT均采用该指标。
  • 5/7项RCT采用每日治疗方案,其中4项每日两次。
  • 研究时长:3项4周,1项5周,1项8个月。
  • GRADE评价为中等确定性证据支持IPC减少下肢水肿、体积或周径。

临床怎么用

  • 对符合纳入标准的慢性下肢淋巴水肿维持期患者,可考虑使用IPC以减少肢体体积。
  • IPC可单独使用或与复杂消肿治疗联合,联合方案在3项RCT中采用。
  • 临床决策时应考虑证据确定性中等及偏倚风险中等。

局限性

  • 纳入RCT异质性大,实验组和对照组构成不同,妨碍荟萃分析。
  • 仅有7项下肢淋巴水肿RCT符合纳入标准,样本量有限。
  • 方法学质量总体为中等,存在中等偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Observational trials have suggested that intermittent pneumatic compression (IPC) devices reduce lymphedema (LED) volume and improve patient-reported outcomes, but this type of trial is subject to bias. Systematic reviews (SRs) of randomized controlled trials (RCTs) provide the highest evidentiary strength for examining the impact of a therapeutic intervention and are important for evidence-based clinical practice guidelines. Few existing SRs, however, include recent RCTs and only a smaller number address LED of the lower extremities (LELED). Therefore, we conducted a SR based on PICO questions to identify RCTs that examined the effect of IPC on LELED for a clinical practice guideline. METHODS: For this SR, English-language RCTs in CINAHL, Embase, and MEDLINE published between January 1, 2010, and January 31, 2025, were searched and the PRISMA reporting method was used. Both intragroup and intergroup comparisons of the specified outcome measures were examined for statistical significance. The evidentiary quality of the RCTs and risk of bias were assessed using GRADE and the Cochrane risk of bias tool, respectively. RESULTS: In the PRISMA analysis, 141 articles were identified through a search of the databases and an additional 4 articles were discovered through other sources, for a total of 145 eligible RCTs. Twenty-one RCTs addressed upper extremity LED and seven LELED RCTs met the criteria for inclusion: adults ≥18 years with unilateral or bilateral chronic LELED and present for ≥6 months and in the maintenance phase of treatment. The patient must have an ankle-brachial index of ≥0.8, have no active infection or acute venous thrombosis, and be able to use the study device and comply with daily therapy. The average total number of patients per RCT was 54, and the mean patient age was 55 years. Female gender predominated (67%). The majority of RCTs were composed of secondary LED, but three series included a segment of primary LED. Chronic venous insufficiency was the most common etiology in the seven RCTs. Five RCTs had two arms, and two had three arms. The experimental arm used an advanced pneumatic compression device in five RCTs, but complex decongestive therapy was combined in this arm with IPC in three. The control comparator arm was complex decongestive therapy in three, a simple IPC in one, and an advanced pneumatic compression device using a different mode in another. Circumferential measurement of limb girth by tape was the most common method to determine volume changes. Five of seven RCTs used a daily treatment regimen, with four using twice daily sessions. Study length varied with 4 weeks in three, 5 weeks in one, and 8 months in another. An a priori power calculation was carried out in three of the seven RCTs. Reduced limb volume was the outcome measure used in all seven studies and all seven showed statistically significant reductions in limb volume when comparing baseline values with end-of-treatment values. Five RCTs also demonstrated differences in their intergroup comparisons of edema reduction. Patient-reported outcomes in five RCTs with three generic quality-of-life (Short Form-36, visual analog scale, and EQ5D3L) and two disease-specific (Lymph ICF-LL and LYMQOL) quality-of-life measures demonstrated significant improvements by intragroup comparison in three RCTs. Heterogeneity and the composition of the experimental and control groups, however, prevented meta-analysis. The methodological quality of the seven RCTs included in this review was evaluated using the Cochrane Risk of Bias Tool. Overall, the included studies demonstrated moderate methodological quality. Assessment of these RCTs by GRADE showed moderate certainty that IPC reduces lower limb edema, volume, or circumference compared with standard care or no IPC. CONCLUSIONS: Despite combining (bundling) additional treatment with IPC in three studies, intragroup comparisons demonstrated highly significant reductions in limb volumes with IPC in all RCTs and in five of seven RCTs by intergroup comparison. Quality indicators demonstrated a moderate risk of bias and moderate certainty.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. O'Donnell TF, Tedesco A, Fish J, et al. A systematic review of contemporary randomized controlled trials for treatment of lower extremity lymphedema by intermittent pneumatic compression devices. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41997536. doi:10.1016/j.jvsv.2026.102500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。